JP2013508353A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508353A5
JP2013508353A5 JP2012535106A JP2012535106A JP2013508353A5 JP 2013508353 A5 JP2013508353 A5 JP 2013508353A5 JP 2012535106 A JP2012535106 A JP 2012535106A JP 2012535106 A JP2012535106 A JP 2012535106A JP 2013508353 A5 JP2013508353 A5 JP 2013508353A5
Authority
JP
Japan
Prior art keywords
composition
autoimmune disease
nucleotide sequence
sequence encoding
mesenchymal stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012535106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508353A (ja
Filing date
Publication date
Priority claimed from KR1020090101194A external-priority patent/KR101301262B1/ko
Application filed filed Critical
Publication of JP2013508353A publication Critical patent/JP2013508353A/ja
Publication of JP2013508353A5 publication Critical patent/JP2013508353A5/ja
Pending legal-status Critical Current

Links

JP2012535106A 2009-10-23 2010-08-27 ＴＧＦβをコーディングするヌクレオチド配列が導入された間葉系幹細胞及びその用途 Pending JP2013508353A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2009-0101194 2009-10-23
KR1020090101194A KR101301262B1 (ko) 2009-10-23 2009-10-23 ＴＧＦβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도
PCT/KR2010/005771 WO2011049291A2 (ko) 2009-10-23 2010-08-27 ＴＧＦβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도

Publications (2)

Publication Number Publication Date
JP2013508353A JP2013508353A (ja) 2013-03-07
JP2013508353A5 true JP2013508353A5 (enExample) 2013-04-25

Family

ID=43900765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535106A Pending JP2013508353A (ja) 2009-10-23 2010-08-27 ＴＧＦβをコーディングするヌクレオチド配列が導入された間葉系幹細胞及びその用途

Country Status (4)

Country Link
US (1) US20120207725A1 (enExample)
JP (1) JP2013508353A (enExample)
KR (1) KR101301262B1 (enExample)
WO (1) WO2011049291A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
AU2014255755B2 (en) * 2013-04-16 2018-10-25 Orbsen Therapeutics Limited Medical use of syndecan-2
KR20150016117A (ko) * 2013-07-30 2015-02-11 코아스템(주) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
WO2015023165A1 (ko) * 2013-08-16 2015-02-19 가톨릭대학교 산학협력단 염증조절복합체 및 ｓｔａｔ３ 신호분자 차단을 통한 면역조절능 최적화된 안정화 중간엽줄기세포
KR101659158B1 (ko) * 2013-08-16 2016-09-23 가톨릭대학교 산학협력단 메트포민이 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
KR20160024147A (ko) 2014-08-25 2016-03-04 가톨릭대학교 산학협력단 강화된 인터류킨―１ 수용체 길항제 생성능을 보유한 중간엽 줄기세포의 제조방법
SG10202106872WA (en) * 2015-02-06 2021-08-30 Kolon Life Science Inc Composition for treating inflammatory disease induced by hyperimmune response
WO2016150884A1 (en) 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
US11918687B2 (en) 2016-01-15 2024-03-05 Orbsen Therapeutics Limited SDC-2 exosome compositions and methods of isolation and use
JP2017200473A (ja) * 2016-04-27 2017-11-09 株式会社Ｃｅｌｌｓ Ｐｏｗｅｒ 活性化幹細胞
US20230111840A1 (en) * 2017-01-30 2023-04-13 Kyoto University Compound, And Method For Producing Regulatory T Cells
AU2018300272B2 (en) 2017-07-14 2024-09-19 Orbsen Therapeutics Limited CD39 stromal stem cells methods of isolation and use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
CA2564679C (en) * 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
WO2007121233A1 (en) * 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
JP2009534394A (ja) * 2006-04-21 2009-09-24 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 結合組織障害の治療
JP2008162983A (ja) * 2006-12-28 2008-07-17 Japan Science & Technology Agency プロジェクターを使った機能的神経ネットワーク構築方法
JP2009001509A (ja) * 2007-06-19 2009-01-08 Univ Nagoya 脂肪組織由来幹細胞を用いた組織再生用組成物

Similar Documents

Publication Publication Date Title
Fernandez-Francos et al. Mesenchymal stem cells as a cornerstone in a galaxy of intercellular signals: basis for a new era of medicine
Lupatov et al. Telomeres and telomerase in the control of stem cells
Fattizzo et al. Mesenchymal stem cells in aplastic anemia and myelodysplastic syndromes: the “seed and soil” crosstalk
MX2023004169A (es) Alteracion de la expresion genetica en celulas t modificadas con el receptor de antigeno quimerico (cart) y usos de las mismas.
WO2017011804A8 (en) Engineered cells for adoptive cell therapy
Greiner et al. Immunological and clinical impact of manipulated and unmanipulated DLI after allogeneic stem cell transplantation of AML patients
Dunavin et al. Mesenchymal stromal cells: what is the mechanism in acute graft-versus-host disease?
MY189819A (en) Genetically modified cells and uses thereof
MX2021006932A (es) Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.
WO2016011210A3 (en) Engineered cells for adoptive cell therapy
WO2011139628A8 (en) Generation of anterior foregut endoderm from pluripotent cells
JP2015131795A5 (enExample)
EA201270713A1 (ru) Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
WO2010051634A9 (en) Human progenitor t-cells
WO2014186469A3 (en) Human application of engineered chimeric antigen receptor (car) t-cells
JP2009511598A5 (enExample)
Seo et al. Strategies to potentiate paracrine therapeutic efficacy of mesenchymal stem cells in inflammatory diseases
Giallongo et al. Engagement of mesenchymal stromal cells in the remodeling of the bone marrow microenvironment in hematological cancers
JP2016501515A5 (enExample)
Saparov et al. The role of antioxidation and immunomodulation in postnatal multipotent stem cell-mediated cardiac repair
EA033437B9 (ru) Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний
Wang et al. Mesenchymal stem cells in acquired aplastic anemia: The spectrum from basic to clinical utility
WO2012075462A3 (en) Methods and compositions for treatment of muscular dystrophy
PL399447A1 (pl) Szczepionka do leczenia cukrzycy typu 1 u dzieci, zastosowanie sortera komórek oraz sposób namnazania komórek Treg do wytwarzania szczepionki do leczenia cukrzycy typu 1
WO2010045573A3 (en) Tumor vaccine